Bioinvent International Ab · OMXSTO:BINV

Bioinvent International Ab — Investor Day (June 2016)

84 slides from Bioinvent International Ab's investor day presentation, Jun 13, 2016

1. Slide 1: R&D Day

   R&D Day 13 June 2016 Michael Oredsson 1 Chief Executive Officer

2. Slide 2: Vi transformerar BioInvent

   Vi transformerar BioInvent Vi har skapat en bred portfölj av kliniska projekt !"#$%&'(')%*$)+,-'#"$)+*"+*"$ ,(-#"$./01 Vi har ökat vårt kommersiella fokus 23")+4"%+$%566#")'#&&+$+#*6$6#- +4+*$%,(-%5(+*%+#" Vi har säkrat finansiering för kommande studier 25")%('(7))+3-8$9,&&+$7*"*(+#"*-$(:#6'))'5($ 5

3. Slide 3: Marknaden för immunonkologi förväntas stiga till >30 mdr USD

   Marknaden för immunonkologi förväntas stiga till >30 mdr USD 3

4. Slide 4: BioInvent utvecklar nästa generations immunonkologiska läkemedel

   BioInvent utvecklar nästa generations immunonkologiska läkemedel Två unika teknologiplattformar Samarbeten med ledande Lång erfarenhet av internationella läkemedelsutveckling n-CoDeR® forskningsgrupper F.I.R.S.T™ 4

5. Slide 5: BioInvents partners

   BioInvents partners 8 Globala 5 4 Pågående Pågående läkemedelsbolag Fas I-studier prekliniska studier som partners p …och ett flertal projekt i discovery-fas ?@$599#(+&'77@5"-$ =*"+(#" 178 Mkr i intäkter 2012-Q12016 ?@$599#(+&'77@5"-$ ?@$599#(+&'77@5"-$ =*"+(#" =*"+(#" 5

6. Slide 6: Tre projekt i klinisk fas under 2016

   Tre projekt i klinisk fas under 2016 BI-1206 BI-505 TB-403 ! A5(BC5-7%'() &:6956 ! L,&+'=#&+ 6:#&56 ! N*(;#"$<5)$K*"( ! D"5(')% &:69*+')% ! E+*"+$*> 9*) FF ! E+*"+$*> 9*) FGFF &#,%#6' ! M==#( )+,-'# ! M==#( )+,-'# ! E+*"+$*>$9*)$FGFF$H.BI$ ./01 ! J#"$63@&'7<#+$*++$ ,+>#;%&*$9&#"$="5-,%+#"$ 93"$*++$&

7. Slide 7: Non-Hodgkins lymfom och kronisk lymfatisk leukemi

   Non-Hodgkins lymfom och kronisk lymfatisk leukemi 7

8. Slide 8: Cancer kan överlista dagens läkemedel…

   Cancer kan överlista dagens läkemedel… 60 000 drabbas av non- Hodgkins lymfom varje år i västvärlden 1/3 av patienterna NOI.K NOI.K dör inom fem år Källa: http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-factors-prognosis 8

9. Slide 9: …men BioInvents antikropp kan överlista cancern

   …men BioInvents antikropp kan överlista cancern Finansierad fas I/II- studie NOI.K 9

10. Slide 10: BI-1206 – Fas II-studie i samarbete med Cancer Research UK

    BI-1206 – Fas II-studie i samarbete med Cancer Research UK O?P$0T$ O?P$.T$ 2FAAX$YZ!!$O[E ?22?D!$[NC$EZD?YC?! J",==$0T$UFB0./1$0$-5)$V$W$ A5(BC5-7%'()B #&&#"$ >#;%5" DPPB=*+'#(+#"$6#-$ Q+#"9*&&$#&&#"$"#9"*%+4" \./$=*+'#(+#" W/B]/$=*+'#(+#" )@,%-56 J",==$.T$UFB0./1$0$-5)$V$W$ RNOI.B=5)'+'>*S >#;%5" '

11. Slide 11: Multipelt myelom

    Multipelt myelom 11

12. Slide 12: Patienter med multipelt myelom drabbas ofta av återfall

    Patienter med multipelt myelom drabbas ofta av återfall Drabbar Revlimid/Velcade Livshotande 40 000 8 MDR blodcancer patienter USD årligen (2014) 12

13. Slide 13: BI–505 kan förhindra eller fördröja återfall

    BI–505 kan förhindra eller fördröja återfall Behandling med cellgifter BI-505 stimulerar immunförsvaret att ”äta upp” cancerceller 13

14. Slide 14: BI-505 kan göra dagens läkemedel effektivare

    BI-505 kan göra dagens läkemedel effektivare _ Finansierad fas II-studie redo för start 14

15. Slide 15: BI-505 – Fas II-studie i samarbete med University of Pennsylvania

    BI-505 – Fas II-studie i samarbete med University of Pennsylvania UFB]/]$ LaP?!$ZY$X!!$2MY?UbJJX =&,)$)+*(-*"-K#<*(-&'(7 ?PP?Y$EFJAF2FDXA!$2MYOYMcX$a!?Y2XPP `/$=*+'#(+#"$6#-$ 6,&+'=#&+$6:#&56 )56$ DPFAFED DPFAFED dY[JY?EEF[AE2YF 7#(567Q"$*,+5&57 ?22?D! ?22?D! Me?YP?eAXO )+*6;#&&)B +"*()=&*(+*+'5($5;

16. Slide 16: Barn med cancer

    Barn med cancer 16

17. Slide 17: Även barn drabbas av cancer

    Även barn drabbas av cancer Medulloblastom Mellan Proteinet Ewings sarkom 30 och 50 PIGF Neuroblastom procent av påverkar Alveolärt patienterna prognosen rhabdomyosarkom avlider negativt 17

18. Slide 18: TB-403 är en antikropp mot PIGF

    TB-403 är en antikropp mot PIGF Finansierad Möjligheter till snabbt fas I/II-studie godkännande redo för start 18

19. Slide 19: Treg & TAM – Nya angreppspunkter

    Treg & TAM – Nya angreppspunkter 19

20. Slide 20: Regulatoriska T-celler (T-regs) – så fungerar det

    Regulatoriska T-celler (T-regs) – så fungerar det Regulatoriska T-celler BioInvents antikroppar Kroppens immunförsvar - dödar cancerceller autoimmuna motverkar infektioner sjukdomar + + 20

21. Slide 21: Tumörassocierade makrofager (TAM) – så fungerar det

    Tumörassocierade makrofager (TAM) – så fungerar det Tumörceller utnyttjar makrofager som skydd BioInvent utvecklar antikroppar som eliminerar eller ändrar funktion på denna typ av makrofager !XL !XL !XL !XL !XL !X !XL !X !XL L !XL !XL !XL !XL !XL CELLGIFT CELLGIFT CELLGIFT CELLGIFT CELLGIFT CELLGIFT

22. Slide 22: Antikroppstillverkning på BioInvent

    Antikroppstillverkning på BioInvent 22

23. Slide 23: Antikroppstillverkning på BioInvent

    Antikroppstilverkning på BioInvent ! Specialiserad på terapeutiska antikroppar ! Mer än 25 års erfarenhet av antikroppsproduktion ! Certifierad GMP-tillverkare sedan 1993 ! Utmärkt track record som leverantör till big pharma och biotech-företag ! Anläggningen godkänd för produktion av prövningsläkem

24. Slide 24: Antikroppstillverkning på BioInvent

    Antikroppstillverkning på BioInvent 1987 ! U'5F(>#(+$K&'"$*%+'>+$=Q$NL[B6*"%(*-#(f 2010 ! 25%,)#"'(7$=Q$'(+#"(*$="5@#%+$5;<$)+"*+#7')%*$=*"+(#"="5@#%+f ! NLNB6*"%(*-#($93"$*(+'%"5==*"$9Q"$#++$,==)>'(7f 2015 ! ^+>#;%&'(7$5;<$="5-,%+'5()%*=*;'+#+$93"$+"#-@#$=*"+f$ ! d"5-,%+'5($93"$K'7 =<*"6*B93"#+*7$=

25. Slide 25: Strategisk rational för BioInvents produktionsanläggning

    Strategisk rational för BioInvents produktionsanläggning Stödja Utnyttja BioInvents överkapacitet för interna program lönsamma och behov av externa prövnings- kundprojekt läkemedel 25

26. Slide 26: Vi transformerar BioInvent

    Vi transformerar BioInvent 26

27. Slide 27: Vi transformerar BioInvent

    Vi transformerar BioInvent Vi har skapat en bred portfölj av kliniska projekt !"#$%&'(')%*$)+,-'#"$)+*"+*"$ ,(-#"$./01 Vi har ökat vårt kommersiella fokus 23")+4"%+$%566#")'#&&+$+#*6$6#- +4+*$%,(-%5(+*%+#" Vi har säkrat finansiering för kommande studier 25")%('(7))+3-8$9,&&+$7*"*(+#"*-$(:#6'))'5($ 5

28. Slide 28: Långsiktig finansiering för fortsatt värdeskapande

    Långsiktig finansiering för fortsatt värdeskapande Riktad emission till Omega Funds (MSEK 43) e4&"#(566#"*-$'(+#"(*+'5(#&&$)=#;'*&')+'(>#)+#"*"# ?"9*"#+$)=#;'*&')+B+#*6$5;<$K#+:-#&)#9,&&+$(4+>#"%$ Fullt garanterad företrädesemission (MSEK 191) J*"*(+#"*-$*>$K& *$D*6="*-B 5;<$N"*955"-B)+'9+#&)#"(*8$

29. Slide 29: Betydande informationsflöde från tre öppna kliniska studier

    Betydande informationsflöde från tre öppna kliniska studier UFB0./1$R(5(BC5-7%'()$&:6956$5;<$DPPS 2*)$FGFF UFB]/]$R6,&+'=#&+$6:#&56S 2*)$FF* !UBW/I$R;*(;#"$<5)$K*"(S 2*)$FGFF 29

30. Slide 30: Tack!

    Tack! 30

31. Slide 31: R&D Day

    R&D Day 13 June 2016 Anna Wickenberg, Ph.D. 1 SVP Clinical Development

32. Slide 32: Agenda – Clinical Development

    Agenda – Clinical Development ! Highlights from ASCO ! Evolving regulatory context ! BI-505 ! Targeting residual disease in Multiple myeloma via ICAM-1 ! BI-1206 ! Treating B cell malignancies through targeting of the inhibitory Fc gamma receptor CD32b ! TB-403 ! Treating patients with relapsing Med

33. Slide 33: Three clinical development stage projects

    Three clinical development stage projects !"#$%&'('%)& !*)+#$, !*)+#$,, -./A2A !"##$%&'()$%#*''+%, 4%&+).!4B/0)8 B"'&+>'$ :($'*:; =-/C26 !"##$%&'()$%#*''+%, 4%&+)D.EF)8 B$@"''*7';<&*:; -./0123 !=4);>>#*?$@ 4%&+)!5617)8 -)9$''):;'+,%;%9+$< 3

34. Slide 34: ASCO reports on immune oncology

    ASCO reports on immune oncology ASCO CHICAGO June 2016 Advance Of The Year: Cancer Immunotherapy 1. unleashing the body’s natural immune response to cancer 2. help the immune system find and destroy cancer cells C 4

35. Slide 35: ASCO highlights for BI, hematology oncology

    ASCO highlights for BI, hematology oncology " Also in the novel agent era, high dose melphalan and autologous stem cell transplantation (ASCT) should remain the preferred treatment for younger patients with newly diagnosed multiple myeloma as it provides clear benefit in PFS and OS (Abstract #8000)

36. Slide 36: Evolving regulatory environment

    Evolving regulatory environment " Fast Track designation " Breakthrough Therapy designation " Accelerated Approval pathway " Priority Review designation " Conditional Marketing Authorization " Accelerated Assessment " Adaptive Pathways pilot " Priority Medicines Scheme (PRIME) 6

37. Slide 37: New drug product approvals 2015

    New drug product approvals 2015 " In total 89 new drugs approved ! 25 were biologics ! 21 approvals within malignant diseases " Examples from heme/onc ! Imbruvica for MCL and CLL ! Venclexta for CLL ! Darzalex for MM 7

38. Slide 38: BI-505: Targeting residual disease in Multiple myeloma via ICAM-1

    BI-505 Targeting residual disease in Multiple myeloma via ICAM-1 8

39. Slide 39: BI-505 executive summary

    BI-505 executive summary !*)+# " DG;<$)..)<&"@()*%,*+%, " !*%<*'+@;&+*%) &#$;&:$%&)*H)>;&+$%&<)I+&G):"'&+>'$) :($'*:;)+%) ,(-'%).'/( 9*:7+%;&+*%) I+&G)G+,G) @*<$):$'>G;';% ;%@)4J=! " K":;%):*%*9'*%;') ;%&+/.!4B/0).,E 0&)++ " 5+#$9&)&":*#/&;#,$&+%,) ;%@).::"%$/:*@"';&*# " .%@"9$<)&":*#) 9$'')@$;&G)LD

40. Slide 40: Rationale for anti-ICAM-1 therapy in myeloma

    Rationale for anti-ICAM-1 therapy in myeloma " Expressed on surface of multiple myeloma plasma cells ! Van Riet et al., BJH, 1991 Huang et al., Cancer Research, 1995 " Mediates protective interactions W$+&*%:XN+ $&);'P)!;%9$#)!$''P)1206 of myeloma cells with bone marrow macrophages ! Contact-depende

41. Slide 41: BI-505 pre-clinical efficacy

    BI-505 pre-clinical efficacy " =#$;&:$%&)I+&G)-./A2A)+%)!"#$!$% :*@$'<)I+&G):"'&+>'$):($'*:;)9$'') '+%$<);%@)>#+:;#():"'&+>'$):($'*:;)9$''<)<+,%+H+9;%&'()#$@"9$)&":*#) ?*'":$)LJ!.5);%@)J!.5/G" :*@$'<M !&#' !&#' -./A2A -./A2A .!4B/0/%$, 9$'')'+%$ !&#' -./A2A W$+&*%:XN+ $&);'P)!;%9$#)!$''P) 1206 11

42. Slide 42: BI-505 MoA in pre-clinical models

    BI-505 MoA in pre-clinical models " Fc:FcgR dependent " Macrophage dependent " Induces bone marrow macrophage infiltration " Induces ADCP (phagocytosis) W$+&*%:XN+ $&);'P)!;%9$#)!$''P)1206 12

43. Slide 43: Phase 1 clinical data

    Phase 1 clinical data " Multi-center dose-escalation study " Advanced relapsed/refractory MM " 34 patients, dose 0.0004 – 20 mg/kg q2w " Mostly grade 1-2 AEs w/o dose relationship " No MTD reached, optimal biologic dose identified (10 mg/kg) based on receptor saturation. " No objective responses; 7/

44. Slide 44: Phase 2 design considerations

    Phase 2 design considerations " Promising pre-clinical efficacy data and attractive MoA to target residual disease " Benign safety profile in patients " No clear single-agent efficacy in phase-1 in advanced R/R patients " Based on MoA, efficacy may be best in targeting low levels of treatment- resis

45. Slide 45: BI-505: phase II study design

    BI-505: phase II study design 06""#(.&7$#("/&&'(5 <&;%@;#@)*H) 9;#$Z)K5B[4J!= Y F*''*I)">)@"#+%,) 6)($;#< -./A2A)02):,ON,)>'"<)<&;%@;#@)*H)9;#$ -+/I$$N'()+%H"<+*%<)L1)>#$/P)a)>*<&/4J!=M SHH+9;9()$?;'";&+*%< " Y$<>*%<$)#;&$< " BY5 \]^2 54b)022 " DFJ Y;%@*:+_$@) 0`0 D#+:;#()$HH+9;9()$?;'";&+*% " QJ "

46. Slide 46: Tumor load is one of the best predictive factors for relapse

    Tumor load is one of the best predictive factors for relapse K;"I$' $&);'P)120C 03 16

47. Slide 47: Acknowledgements

    Acknowledgements " Alfred Garfall, MD " Brendan Weiss, MD " Edward Stadtmauer, MD " Nina Luning Prak, MD PhD 17

48. Slide 48: BI-1206: Treating B cell malignancies, CLL/NHL, through CD32B

    BI-1206 Treating B cell malignancies, CLL/NHL, through targeting of the inhibitory Fc gamma receptor CD32B 18

49. Slide 49: BI-1206 executive summary

    BI-1206 executive summary !*)+# " DG;<$).O..; <&"@()&*)7$)+%+&+;&$@P)!=4);>>#*?$@ ,(-'%).'/( " !5617)>*<+&+?$)-)9$''):;'+,%;%9+$< " K":;%):*%*9'*%;') ;%&+/!5617 0&)++ " 5+#$9&)&":*#/&;#,$&+%,) ;%@).::"%$/:*@"';&*# " .%@"9$<)&":*#) 9$'')@$;&G)LD!5P)45!!);%@)45!DM 1/-#$/2$3%.'/($ " .%G+7+&<)+%&$#%;'+_

50. Slide 50: Rationale for anti-CD32B therapy in B cell malignancies

    Rationale for anti-CD32B therapy in B cell malignancies " CD32b is expressed throughout B cell development and in different B cell cancers " CD32b is a negative regulator of therapeutic antibody efficacy, operating both on tumor and immune cells, and BI-1206 blocks this. " Tumor CD32b expression pre

51. Slide 51: Rationale for anti-CD32B therapy with BI-1206

    Rationale for anti-CD32B therapy with BI-1206 " CD32b is expressed throughout B cell development and in different B cell cancers " CD32b is a negative regulator of therapeutic antibody efficacy, operating both on tumor and immune cells, and BI-1206 blocks this. " Tumor CD32b expression predicts clin

52. Slide 52: Rationale for anti-CD32B therapy

    Rationale for anti-CD32B therapy FVP)Y)9*%&;+%+%,)#$,+:$%P)\]01^ " CD32b is expressed throughout B cell development and in different B cell cancers " CD32b is a negative regulator of therapeutic antibody efficacy, operating both on tumor and immune cells, and BI-1206 blocks this. " CD32b expression

53. Slide 53: Phase 1/2a design considerations

    Phase 1/2a design considerations " Promising pre-clinical efficacy data and attractive MoA for B cell lymphomas with strong data in CLL and MCL models " No significant preclincial toxicology findings " First In Man study " Efficacy may be best in combination with tumor targeting mAb, like anti- CD20

54. Slide 54: A signal seeking Phase I/IIa safety Study with BI-1206 and rituximab

    A signal seeking Phase I/IIa safety Study with BI-1206 and rituximab in Patients with CD32b+ B cell malignancy " First In Man " 5-8 sites in UK is planned to participate " Coordinating PI – Prof Andrew Davies, Southampton 24 1C

55. Slide 55: BI-1206: phase I/IIa study design, part A

    BI-1206: phase I/IIa study design, part A " Q7g$9&+?$)+<)&*)+%?$<&+,;&$)<;H$&();%@)+@$%&+H()*>&+:;') @*<$)H*#)>G;<$).. S 5*<$)$<9;';&+*%P)6[6)@$<+,% B;+%&$%;%9$)">)&*)0b C)I$$N'()+%H"<+*%< S?$#()c&G I$$N)+%H"<+*% \]">)&*)0^ dSSf)c bS4Y)0 " J;H$&();%@)&*'$#;7+'+&( S?;'";&+*% " Y$<>*%<$)#;&$< DFJ);%@)

56. Slide 56: BI-1206: phase I/IIa study design, part B

    BI-1206: phase I/IIa study design, part B " Q7g$9&+?$)+<)&*)+%?$<&+,;&$)<;H$&();<)<+%,'$);,$%&);%@)+%)9*:7+%;&+*%) I+&G)#+&"h+:;7P) ;%@)@*9":$%&) ;%&+/&":*#);9&+?+&();%@)<+,%;'<)*H)$HH+9;9( J+%,'$) ;,$%&)-./0123 B;+%&$%;%9$)">)&*)0b Y !*:7+%;&+*%Z) -./0123)>'"<);%&+)!512 B;+%&$%;%9$)">)&*)0b C)I$$N'

57. Slide 57: Acknowledgements

    Acknowledgements " Andrew Davies, PhD, MD " Investigators and staff at all sites " Hayley Farmer, PhD " CRUK team 27

58. Slide 58: TB-403: Treating relapsing Medulloblastoma via PlGF/Nrp1

    TB-403 Treating patients with relapsing Medulloblastoma through blockade of the PlGF/Nrp1 pathway 28

59. Slide 59: TB-403 executive summary

    TB-403 executive summary !*)+# " DG;<$).O..; <&"@()+%+&+;&$@ ,(-'%).'/( " =#$;&:$%&)*H)#$';><$@)*#)#$H#;9&*#()>;&+$%&<)I+&G):$@"''*7';<&*:; " K":;%+_$@) :*%*9'*%;') ;%&+/D'EF 0&)++ " J"#?+?;')<+,%;')7'*9N+%, " -+%@<)D'EF ;%@)7'*9N<)+&<)<"#?+?;');%@),#*I&G)<+,%;'+%,) ?+;)\#>/0) 1/-#$/2$3%.'/($ #$9$>&

60. Slide 60: Rationale for anti-PlGF therapy in medulloblastoma

    Rationale for anti-PlGF therapy in medulloblastoma " TB-403 treatment led to inhibition of primary tumor growth and spinal metastasis and longer survival " PlGF activates prosurvival pathways in Medulloblastoma through NRP1 " NRP1 expression is linked to poor survival in children with medulloblastom

61. Slide 61: Phase-1/2a design considerations

    Phase-1/2a design considerations " Promising pre-clinical efficacy data " Tested in clinical trials in adult populations with no significant safety findings " Higher doses are needed to reach tumor site in medulloblastoma " Challenges in recruitment of pediatric medulloblastoma population foreseen !

62. Slide 62: TB-403: phase I/IIa study design, part A

    TB-403: phase I/IIa study design, part A 06""#(.&7$#("/&&'(5 " Q7g$9&+?$)+<)&*)+%?$<&+,;&$)<;H$&();%@)+@$%&+H()B=5)@*<$)H*#)>G;<$).. S 5*<$)$<9;';&+*%P)6[6)@$<+,% B;+%&$%;%9$)">)&*)3):* 1)7+/I$$N'()+%H"<+*%<)L*%$)1c@/9(9'$M -+/I$$N'()+%H"<+*%)[)9*:7+%;&+*%)I)J*! \])">)&*)0A Y$';><$@)>;&+$%&<)I+&G)B-

63. Slide 63: TB-403: phase I/IIa study design, part B

    TB-403: phase I/IIa study design, part B " Q7g$9&+?$)+<)&*)+%?$<&+,;&$)<;H$&();%@)<+,%)*H)$HH+9;9( J+%,'$) ;,$%&)=-)C26 B;+%&$%;%9$)">)&*)3):* C)7+/I$$N'()+%H"<+*%<)L1)9(9'$<M -+)I$$N'()+%H"<+*%<)[))9*:7+%;&+*%)I)J*! dSSf)c BQ\=K)3 Y$';><$@)B- D#+:;#()$?;'";&+*% S?;'";&+*% \]01 " J;H$&();%@)&*'$#;7+

64. Slide 64: Acknowledgements

    Acknowledgements " Giselle Scholler, MD " Amy Lee Bredlau, MD " NMTRC investigators and staff 34

65. Slide 65: Tack

    Tack 35

66. Slide 66: R&D Day

    !"#$%&'%( )*"'%*' +,-.("'%(,*'%(/"*,(/.%)0.("#%.0,1/23, R&D 1")*#&'/4,.--/#.*5,"%('3/.("%3, .%("6#1478,(./3'(78,.%1,1")'.)', Day 13 June 2016 6"#0#34 Björn Frendéus, Ph. D. 1 Chief Scientific Officer

67. Slide 67: The BioInvent drug development offer

    The BioInvent drug development offer – cutting edge, highly integrated, translational science 92(("%37'13',:/.%)0.("#%.0, E/";./4,E.("'%(,C.('/".0) 9#;6"%'1,:./3'(,.%1,F/23, 9.%*'/,$;;2%#0#34,<*"'%*' = J'007')(.60")5'18,0#%37)(.%1"%38, F")*#&'/4 = >"3504,'?-'/"'%*'1, @%*#0#34,('.;, %'(A#/K,.%1,*#00.

68. Slide 68: Why antibodies?

    Why antibodies? Antibodies to checkpoint inhibitors have transformed cancer therapy ! S'/&#4 T.%("79:U+7VW8,.%("7EFX,.%1,.%("7EFUX,Y*5'*K-#"%(, "%5"6"(#/Z,.%("6#1"'), "%12*', 0#%370.)("%3, /';"))"#%), "%,('/;"%.004, "00,*.%*'/,-.("'%()P [#%7 /')-#%1'/ /')-#%1'/ ! <"3%"H"*.%(, H/.*("#%,#H,*.%*'/)D,*.

69. Slide 69: Mechanisms of resistance/unresponsiveness to checkpoint inhibitor therapy

    Mechanisms of resistance/unresponsiveness to checkpoint inhibitor therapy Intrinsic resistance (including cancer type specific, e.g. Colorectal, Pancreatic, TNBC) ! Immune suppressive tumor microenvironment " Tumor-associated myeloid cells, Treg ! Low immunogenicity of tumor cells " Low (immunogenic

70. Slide 70: Role of FcγRIIB, Treg and TAM in the cancer-immunity cycle

    Role of FcγRIIB, Treg and TAM in the cancer-immunity cycle +1.-('1,H/#;,95'%, .%1,C'00;.%8, $;;2%"(48,]^X\ 5

71. Slide 71: The BioInvent offering: From bedside, to bench, to bedside

    The BioInvent offering: From bedside, to bench, to bedside 3$%4,.561015+6 )%761015+6% !"#$%&'( 8.9.62:&.0* )*+***+***+***,-./ !0:%+,$ VP,$%,&"&# E#9 #$%&'( )%*+,-.*/%-.0.,+*120 9!"%+,$ OP$PLP<P:Q E/'71'H"%'1, E.("'%(,*'00) !"#-.%%"%3_ (./3'() !"""#$%&'()&* +,$ ;$%<+,-.*%1=.0*1>15+*120 9!""%&'()&* +,

72. Slide 72: The F.I.R.S.T™ platform: Combined target and antibody discovery

    The F.I.R.S.T™ platform: Combined target and antibody discovery $%-2(b, XW E5.3',1")-0.4,0"6/./48,%79#F'L!8,A"(5,X^X^ 52;.%,)*O& * ]W :./3'(,*'00),TYF")'.)'ZW,.%1,[#%7(./3'(,*'00),TY>'.0(54ZW F"HH'/'%(".0,*'00,-.%%"%3, T:./3'( &),[#%7(./3'(W,(#, ) ")#0.(',-##0), #H,)*O& H/#;,-5.3',1")-0.4,0"6/./4 9'

73. Slide 73: The F.I.R.S.T™ Immune Oncology platform

    The F.I.R.S.T™ Immune Oncology platform #? #?V^ V7 X! ! 8

74. Slide 74: F.I.R.S.T™ Bench to Bedside example

    F.I.R.S.T™ Bench to Bedside example OP$PLP<P:Q 9UU,c $1'%("H"*.("#%,#H,(5',$%5"6"(#/4,O*,3.;;.,/'*'-(#/, TO*3L$$!8,9F\]6W,.),.,-/#;")"%3,(./3'(,H#/,(5'/.-4,#H,!,*'00,;.0"3%.%*4 Overcoming Resistance to Antibody Therapy 9

75. Slide 75: F.I.R.S.T™ CLL target identification

    #6/&,/7AC> 3 F.I.R.S.T ™ CLL target identification #DD '87AB8@6. 78?EE% '87AB8@6. '877%FGH X^ 10

76. Slide 76: Several Activating but only one inhibitory FcgR

    Several Activating but only one inhibitory FcgR G G G G G G G G G G G G G G G G G G G G G G G G G G G G G FcG receptors asG regulators G of immune responses G Falk Nimmerjahn* and Jeffrey V. Ravetch‡ | JANUARY Abstract 34 2008to| their | In addition VOLUMErole in 8binding antigen, antibodies can reg

77. Slide 77: FcgRIIb de-sensitizes immune effector cells and mutes antibody activity

    FcgRIIb de-sensitizes immune effector cells and mutes antibody therapeutic activity XP,$%(/.&'%#2),"%I'*("#%, #H,TO*γL7 A( D7W,!Xd,;'0.%#;.,*'00,0"%' γ 7D7 O*γL$$6 7D7 ] $ ]P,$%(/.&'%#2),"%I'*("#%, " I " #H,.%("7 H ;'0.%#;.,.%("3'%,$3a 904%')8, [.(,C'18,]^^^ 12

78. Slide 78: FcgRIIb on target B-cells reduces rituximab efficacy through internalization

    FcgRIIb on target B-cells reduces rituximab efficacy through internalization C.%(0',*'00,04;-5#;. L#35.%".%8,9.%*'/,9'008, ]^X` U";8,!0##18, ]^XX 13 U''8,!/,e,>';.(#08,]^XV

79. Slide 79: In vivo Proof-of-concept

    In vivo Proof-of-concept EF")0*4,5GHIJHF-HI=,'FHK<FL-E,E,#IDD,%I5DIHFGJ,FJ, FLLKJG#GL5IHIJH,M#%10NM#%0*NL#%10E";" LF#I C'*5.%");,$,f,$$,f,$$$ C ''*5 5.%"");,$$,f,$$$,ff,$$$ L#35.%".%8,9.%*'/,9'008, ]^X` 14

80. Slide 80: BI-1206 enhances therapeutic activity of clinically relevant antibodies

    BI-1206 enhances therapeutic activity of clinically relevant antibodies against different targets in vivo 15

81. Slide 81: 14-BI-1206-1: Phase I/IIa safety study with BI-1206 and rituximab

    14-BI-1206-1: A signal seeking Phase I/IIa safety study with BI-1206 and rituximab in CD32b positive B-cell malignancies +,;20("*'%('/,H"/)(,"%,;.%8,#-'%,0.6'08,(A#,-./(8,-5.)', $D$$. )(214,"%,-.("'%(),A"(5,/'0.-)'1,#/,/'H/.*(#/4, 9F\]6,-#)"("&',!7*'00,;.0"3%.%*"') ! 56O7,-b,<"%30',.3'%(,!$7X]^d,1#)

82. Slide 82: BI-505: Combatting residual disease by targeting ICAM-1

    BI-505: Combatting residual disease by targeting ICAM-1 and macrophage scavenging of myeloma ::E :/".0,"%,);#01'/"%3, I27 6.+=10-%*2%*A&2A, E5.)',$, (A,=.0%,.=A5*120%+0=% -.("'%()) #H,/')-#%)' CC F'-(5, ,.B:20B. A3; A3; B%>50?"? CLF !$7`^`,C#+ XP +*("&.('),;.*/#-5.3'),"%,!C,*#;-./(;'%()8,A5"*5,"%,(5

83. Slide 83: T REG program outline

    TREG program outline XP O$L<::C 3'%'/.("#%,#H,:,/'3 (./3'("%3,.%("6#1"') ! >2;.%,7 H#/,0'.1,*.%1"1.(',)'0'*("#%)P, U./3',-.%'0,A"(5,&./"'1,6"%1"%3,-.(('/% ! C#2)',7 H#/,"%,&"&#,-#* "%,)4%3'%'"*,;#2)',;#1'0)P,U./3',-.%'0,A"(5,&./"'1, :./3'(,1")*#&'/4 6"%1"%3,-.(('/% a'%'/.("#%,#H,;+6 .3."%)(,)'0'*('1

84. Slide 84: F.I.R.S.T™ TAM

    F.I.R.S.T™ TAM ! :2;#/ +))#*".('1 C.*/#-5.3') T:+Ch)W ./' -/#7(2;#/"3'%"*8 '%5.%*' (2;#/ 3/#A(5 .%1 -/#3/'))"#%8 .%1 1'*/'.)' 'HH"*.*4 #H &./"#2) .%("*.%*'/ (5'/.-"')P ! C#/' (5.% `^j #H (5' (2;#/ ;.)) *.% 6' ;.1' 2- #H ;4'0#"1 *'00) A"(5 ";;2%' )2--/'))"&' -/#(2;#/ .*("&"(4 ! :5' 1'%)"(4 #H ;.*/#-5

BioInvent International — Investor Day (June 2016) on 6ix